Skip to main content

Bayer-Genzyme Deal Yields Access to Small-Molecule Library

Premium

LEVERKUSEN, Germany--Bayer here has announced a collaboration with Genzyme to accelerate identification of drug development targets. Candidates will come from Genzyme's small-molecule compound library and be analyzed with Bayer's high-speed robotic screening equipment. The deal could be worth as much as $35 million to Genzyme in fees and milestone payments, the company said.

Terms of the collaboration include an up-front payment to Genzyme for access to the company's library, with milestone payments coming as selected compounds proceed through clinical trials. "The unique chemistry technology developed by Genzyme is an ideal combination with Bayer's expertise in high-technology robotic screening methods," commented Wolfgang Hartwig, Bayer's head of worldwide pharmaceutical research.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.